论文部分内容阅读
目的:探讨Graves病患者6h/24h摄131I率比值与其性别、年龄、甲状腺肿大程度、TT3、TT4、FT3和FT4的相关性,找出6h/24h摄131I率比值的影响因素并作为计算131I治疗Graves病剂量的参考依据。方法:测定160例Graves病患者6,24h摄131I率、TT3、TT4、FT3和FT4。应用SPSS13.0软件对6h/24h摄131I率比值与其临床相关指标进行相关分析。结果:在单因素分析中6h/24h摄131I率比值与性别、甲状腺肿大程度、TT3、TT4、FT3和FT4呈正相关关系,与年龄呈负相关关系,多元逐步分析提示6h/24h摄131I率比值与FT3呈正相关关系,与年龄呈负相关关系。结论:131I治疗FT3水平较高的Graves病患者需增加治疗剂量。
OBJECTIVE: To investigate the correlation between the 131I rate at 6h / 24h and the sex, age, goiter, TT3, TT4, FT3 and FT4 in patients with Graves disease and to find out the influencing factors of 131I rate at 6h / 24h and calculate 131I References for treatment of Graves disease dose. Methods: The 131I rate, TT3, TT4, FT3 and FT4 in 160 patients with Graves’ disease at 6 and 24 h were measured. SPSS13.0 software was used to correlate the 131I rate of 6h / 24h with its clinically relevant indexes. Results: In the univariate analysis, the ratio of 131I at 6h / 24h was positively correlated with gender, thyroid enlargement, TT3, TT4, FT3 and FT4, and negatively correlated with age. Multiple stepwise analysis showed 131I rate at 6h / 24h The ratio was positively correlated with FT3 and negatively correlated with age. Conclusion: 131I treatment of Graves disease patients with higher levels of FT3 need to increase the therapeutic dose.